These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 14658944)
1. Partial compliance and patient consequences in schizophrenia: our patients can do better. Keith SJ; Kane JM J Clin Psychiatry; 2003 Nov; 64(11):1308-15. PubMed ID: 14658944 [TBL] [Abstract][Full Text] [Related]
2. A review of pharmacologic strategies for switching to atypical antipsychotics. Masand PS Prim Care Companion J Clin Psychiatry; 2005; 7(3):121-9. PubMed ID: 16027767 [TBL] [Abstract][Full Text] [Related]
3. Partial compliance in schizophrenia and the impact on patient outcomes. Llorca PM Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080 [TBL] [Abstract][Full Text] [Related]
4. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. Turner MS; Stewart DW J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985 [TBL] [Abstract][Full Text] [Related]
5. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Achilla E; McCrone P Appl Health Econ Health Policy; 2013 Apr; 11(2):95-106. PubMed ID: 23494934 [TBL] [Abstract][Full Text] [Related]
6. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Masand PS; Gupta S Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433 [TBL] [Abstract][Full Text] [Related]
7. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914 [TBL] [Abstract][Full Text] [Related]
8. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics. De Hert M; Sermon J; Geerts P; Vansteelandt K; Peuskens J; Detraux J CNS Drugs; 2015 Aug; 29(8):637-58. PubMed ID: 26293744 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A; Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869 [TBL] [Abstract][Full Text] [Related]
10. Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Taylor M; Ng KY Aust N Z J Psychiatry; 2013 Jul; 47(7):624-30. PubMed ID: 23209308 [TBL] [Abstract][Full Text] [Related]
11. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. Kane JM J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417 [TBL] [Abstract][Full Text] [Related]
13. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Keith SJ; Pani L; Nick B; Emsley R; San L; Turner M; Conley R; Scully P; Chue PS; Lachaux B Psychiatr Serv; 2004 Sep; 55(9):997-1005. PubMed ID: 15345759 [TBL] [Abstract][Full Text] [Related]
14. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745 [TBL] [Abstract][Full Text] [Related]
15. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Bhanji NH; Chouinard G; Margolese HC Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023 [TBL] [Abstract][Full Text] [Related]